KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. (KALV) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · KALV · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
55
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
KalVista Pharmaceuticals, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
KALV insider buying and selling by quarter
KALV insider selling · KALV insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · KALV ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
KALV executive sell shares · KALV board member insider trading · KALV insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 27, 2026 | Yea Christopher CHIEF DEVELOPMENT OFFICER | Option | 33,800 | $239K | Form 4 |
| May 27, 2026 | Yea Christopher CHIEF DEVELOPMENT OFFICER | Sale | 33,800 | $905K | Form 4 |
| May 22, 2026 | Yea Christopher CHIEF DEVELOPMENT OFFICER | Option | 3,125 | — | Form 4 |
| May 26, 2026 | Yea Christopher CHIEF DEVELOPMENT OFFICER | Sale | 1,966 | $53K | Form 4 |
| May 22, 2026 | Sweeny Nicole Chief Commercial Officer | Option | 5,000 | — | Form 4 |
| May 26, 2026 | Sweeny Nicole Chief Commercial Officer | Sale | 1,489 | $40K | Form 4 |
| May 22, 2026 | Audhya Paul K. CHIEF MEDICAL OFFICER | Option | 5,000 | — | Form 4 |
| May 26, 2026 | Audhya Paul K. CHIEF MEDICAL OFFICER | Sale | 2,239 | $60K | Form 4 |
| May 21, 2026 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER · Director | Option | 23,250 | — | Form 4 |
| May 22, 2026 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER · Director | Sale | 10,926 | $293K | Form 4 |
| May 21, 2026 | Sweeny Nicole Chief Commercial Officer | Option | 6,250 | — | Form 4 |
| May 22, 2026 | Sweeny Nicole Chief Commercial Officer | Sale | 1,861 | $50K | Form 4 |
| May 21, 2026 | Yea Christopher CHIEF DEVELOPMENT OFFICER | Option | 3,750 | — | Form 4 |
| May 22, 2026 | Yea Christopher CHIEF DEVELOPMENT OFFICER | Sale | 2,358 | $63K | Form 4 |
| May 21, 2026 | Audhya Paul K. CHIEF MEDICAL OFFICER | Option | 6,250 | — | Form 4 |
| May 22, 2026 | Audhya Paul K. CHIEF MEDICAL OFFICER | Sale | 2,685 | $72K | Form 4 |
| May 21, 2026 | Piekos Brian CFO | Option | 5,000 | — | Form 4 |
| May 22, 2026 | Piekos Brian CFO | Sale | 1,489 | $40K | Form 4 |
| May 17, 2026 | Yea Christopher CHIEF DEVELOPMENT OFFICER | Option | 1,774 | — | Form 4 |
| May 18, 2026 | Yea Christopher CHIEF DEVELOPMENT OFFICER | Sale | 1,108 | $30K | Form 4 |
| May 17, 2026 | Audhya Paul K. CHIEF MEDICAL OFFICER | Option | 2,419 | — | Form 4 |
| May 18, 2026 | Audhya Paul K. CHIEF MEDICAL OFFICER | Sale | 1,032 | $28K | Form 4 |
| May 17, 2026 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER · Director | Option | 2,419 | — | Form 4 |
| May 18, 2026 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER · Director | Sale | 1,129 | $30K | Form 4 |
| May 11, 2026 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER · Director | Option | 7,120 | — | Form 4 |
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Date
May 27
Shares
33,800
Price
$7.07
Value
$239K
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Date
May 27
Shares
33,800
Price
$26.78
Value
$905K
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Date
May 22
Shares
3,125
Price
—
Value
—
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Date
May 26
Shares
1,966
Price
$26.78
Value
$53K
Sweeny Nicole
Chief Commercial Officer
Date
May 26
Shares
1,489
Price
$26.78
Value
$40K
Audhya Paul K.
CHIEF MEDICAL OFFICER
Date
May 26
Shares
2,239
Price
$26.78
Value
$60K
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER · Director
Date
May 21
Shares
23,250
Price
—
Value
—
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER · Director
Date
May 22
Shares
10,926
Price
$26.78
Value
$293K
Sweeny Nicole
Chief Commercial Officer
Date
May 22
Shares
1,861
Price
$26.78
Value
$50K
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Date
May 21
Shares
3,750
Price
—
Value
—
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Date
May 22
Shares
2,358
Price
$26.78
Value
$63K
Audhya Paul K.
CHIEF MEDICAL OFFICER
Date
May 22
Shares
2,685
Price
$26.78
Value
$72K
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Date
May 17
Shares
1,774
Price
—
Value
—
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Date
May 18
Shares
1,108
Price
$26.76
Value
$30K
Audhya Paul K.
CHIEF MEDICAL OFFICER
Date
May 18
Shares
1,032
Price
$26.76
Value
$28K
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER · Director
Date
May 17
Shares
2,419
Price
—
Value
—
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER · Director
Date
May 18
Shares
1,129
Price
$26.76
Value
$30K
Palleiko Benjamin L
CHIEF EXECUTIVE OFFICER · Director
Date
May 11
Shares
7,120
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About KALV insider trading
KALV insider trades
KalVista Pharmaceuticals, Inc. (KALV) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Palleiko Benjamin L (CHIEF EXECUTIVE OFFICER · Director), Yea Christopher (CHIEF DEVELOPMENT OFFICER), Audhya Paul K. (CHIEF MEDICAL OFFICER). Over the past 12 months, 5 insiders have filed transactions with the SEC. KALV insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For KalVista Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
KALV insider trading · 5 questionsThe insiders of KalVista Pharmaceuticals, Inc. (KALV) include executives and directors such as Palleiko Benjamin L (CHIEF EXECUTIVE OFFICER · Director), Yea Christopher (CHIEF DEVELOPMENT OFFICER), Audhya Paul K. (CHIEF MEDICAL OFFICER), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026